“A insufici\u00eancia card\u00edaca (IC), t\u00e3o frequente no atendimento ambulatorial, possui um restrito arsenal terap\u00eautico com comprovada efic\u00e1cia na redu\u00e7\u00e3o da mortalidade em pacientes com insufici\u00eancia card\u00edaca com fra\u00e7\u00e3o de eje\u00e7\u00e3o reduzida e, principalmente, na insufici\u00eancia card\u00edaca com fra\u00e7\u00e3o de eje\u00e7\u00e3o preservada. Na \u00faltima d\u00e9cada a ind\u00fastria farmac\u00eautica mostrou avan\u00e7os no desenvolvimento de novas terap\u00eauticas para um melhor manejo desta patologia. Dentre estas novas op\u00e7\u00f5es temos os inibidores do cotransportador s\u00f3dio-glicose tipo 2 (SGLT2) com evid\u00eancia de potencial redu\u00e7\u00e3o da morbimortalidade na IC. O departamento de cardiologia da AMP traz aos seus associados os artigos originais dos primeiros resultados desta classe no tratamento da IC (Emperor-reduced e DAPA) al\u00e9m de uma sele\u00e7\u00e3o de artigos recentes que avaliaram o impacto dos SGLTS no manejo da IC.”<\/p>\n

Dr. T\u00falio Reichert – Presidente do Depto. de Cardiologia e Cirurgia Cardiovascular da AMP<\/p>\n

Acesse os artigos na \u00edntegra:<\/p>\n

Empagliflozin in Heart Failure with a Preserved Ejection Fraction
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2107038?articleTools=true<\/a><\/p>\n

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2022190?articleTools=true<\/a><\/p>\n

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
\nhttps:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa1911303?articleTools=true<\/a><\/p>\n

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
\nhttps:\/\/www.jacc.org\/doi\/epdf\/10.1016\/j.jacc.2021.07.049<\/a><\/p>\n

Prognostic Importance of NT-proBNP and\u00a0Effect of Empagliflozin in the EMPEROR-Reduced Trial
\nhttps:\/\/reader.elsevier.com\/reader\/sd\/pii\/S0735109721057843?token=F2DEC2CA66E4B96FC435786642A1834D059751DF98B3A9402DE49F31832B309707921E43512AF8FBCD72B39AAAD22FAB&originRegion=us-east-1&originCreation=20220810200020<\/a><\/p>\n

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
\n<\/strong><\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9311476\/<\/a><\/p>\n

Eligibility for Dapagliflozin and Empagliflozin in a Realworld Heart Failure Populatio
\nwww.onlinejcf.com\/action\/showPdf?pii=S1071-9164%2822%2900504-8<\/a><\/p>\n

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9288802\/<\/a><\/p>\n

Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
\nhttps:\/\/www.ahajournals.org\/doi\/epub\/10.1161\/CIRCULATIONAHA.122.059038<\/a><\/p>\n

Empagliflozin Improves Outcomes in\u00a0Patients With Heart\u00a0Failure and Preserved Ejection Fraction Irrespective of Age
\nhttps:\/\/doi.org\/10.1016\/j.jacc.2022.04.040<\/a><\/p>\n

\u00a0<\/strong><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

“A insufici\u00eancia card\u00edaca (IC), t\u00e3o frequente no atendimento ambulatorial, possui um restrito arsenal terap\u00eautico com comprovada efic\u00e1cia na redu\u00e7\u00e3o da mortalidade em pacientes com insufici\u00eancia card\u00edaca com fra\u00e7\u00e3o de eje\u00e7\u00e3o…<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[26],"tags":[],"_links":{"self":[{"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/posts\/6313"}],"collection":[{"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/comments?post=6313"}],"version-history":[{"count":10,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/posts\/6313\/revisions"}],"predecessor-version":[{"id":6334,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/posts\/6313\/revisions\/6334"}],"wp:attachment":[{"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/media?parent=6313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/categories?post=6313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ampdigital.org\/wp-json\/wp\/v2\/tags?post=6313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}